Princeton, N.J. – September 6, 2022 – Mapi Research Trust is proud to support WCG Clinical Endpoint Solutions in the development of 27 electronic versions (eCOA) of Clinical Outcome Assessments (COAs), which are used to measure how a patient feels or functions. The team of experts from Mapi Research Trust will collaborate with WCG’s world-renowned scale authors and assessment experts to ensure the COA’s integrity is maintained and that the eCOA system has been adequately designed. After review and certification by Mapi Research Trust, information on those eCOAs will be added in the PROQOLIDTM COA database under the relevant “e-Versions” sections to continuously facilitate the exchange and access to information in the field of COAs for the entire scientific community.
“With 30 years of experience in the field of COAs, we have established close collaborations with COA authors who are key to a seamless and robust digitalization of COAs. From COA licensing to eCOA testing and maintenance of up-to-date versions, our relationships with authors facilitate the whole process of eCOA development and ensure that the COA’s integrity and measurement properties are respected.” explains Sonia Bothorel, Managing Director of Mapi Research Trust. “WCG can leverage our expertise to support the provision of the best possible eCOA experience to their clients and ultimately to their patients; for their voice to be properly collected and considered for drug development.”
WCG’s Clinical Endpoint Solutions help sponsors reduce the risk of trial failure for clinical trials with subjective endpoints through their eCOA/ePRO platform, clinical assessments, rater and patient training, and Study Insight Analytics platform. Working in closely with their clients, WCG has developed industry-leading eCOA solutions with rapid setup, easy deployment, improved patient engagement and an ever expanding eCOA library. provides digital clinical outcome assessments (eCOA) and data management for clinical trials.
“We are thrilled to collaborate with Mapi Trust to further expand the library of our proprietary eCOA/ePRO solutions,” said Mark Opler, Chief Research Officer at WCG. “Our scientific and clinical experts rely on our robust proprietary technology platforms to help sponsors reduce the risk of failure of clinical trials and support the successful development of life-saving therapies.”
Chief Marketing Officer, WCG
About Mapi Research Trust
Mapi Research Trust is a non-profit organization founded to promote the use of Clinical Outcomes Assessments (COAs) in health research and practice and encourages exchanges of Patient-Centered Outcomes and COA information among academics, pharmaceutical companies, health care organizations and health authorities. With the web-based platform ePROVIDE™ that includes the databases PROQOLID™, PROLABELS™, and PROINSIGHT™, Mapi Research Trust has become the preeminent source of reliable, up-to-date and comprehensive information about COAs.
Mapi Research Trust is the largest single COA licensing provider and the most trusted name in distribution of COA instruments exclusively representing over 670 COAs.
WCG is the world’s leading provider of solutions that measurably improve the quality and efficiency of clinical research. Comprised of two divisions, the industry’s first central IRB – WCG IRB – and first clinical services organization, WCG enables biopharmaceutical companies, CROs, and institutions to advance the delivery of new treatments and therapies to patients, while maintaining the highest standards of human participant protection. For more information, please visit www.wcgirb.com, www.wcgclinical.com or follow us on Twitter @WCGClinical or LinkedIn.